Shi‐Xiong Liang

Guangxi Medical University

Papers

2

Total Citations

43

H-Index

2

About

Dr. Shi‐Xiong Liang is a leading radiation oncologist whose research focuses on advanced radiotherapy techniques for hepatocellular carcinoma (HCC), particularly in cases complicated by portal vein tumor thrombosis (PVTT)—a condition historically associated with poor prognosis. His landmark 2021 study, which has garnered over 40 citations, provides critical comparative evidence between stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT) for HCC with PVTT. This work directly addresses a pressing clinical challenge by demonstrating the safety and efficacy of SBRT in this high-risk population, offering a non-invasive alternative that can improve tumor control and survival outcomes. Dr. Liang’s contributions are pivotal in refining treatment paradigms for advanced liver cancer, where conventional therapies often fall short. His research not only advances the field of radiation oncology but also provides actionable insights for clinicians managing complex HCC cases. With a citation impact that underscores the relevance of his findings, Dr. Liang continues to shape evidence-based practice in hepatobiliary oncology, bridging the gap between technological innovation and patient-centered care.

Research Focus

Key Achievements

2
H-Index
2
Papers
43
Total Citations
22
Avg Citations/Paper
🏆 Most Cited Paper
Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis
41 citations · 2021
📈 Most Prolific Year: 2021 (2 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Guangxi Medical University

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago